SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-036500
Filing Date
2023-10-06
Accepted
2023-10-06 16:10:32
Documents
13
Period of Report
2023-10-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44897
2 ex10-1.htm EX-10.1 182270
  Complete submission text file 0001493152-23-036500.txt   440421

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE aneb-20231005.xsd EX-101.SCH 3012
4 XBRL LABEL FILE aneb-20231005_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE aneb-20231005_pre.xml EX-101.PRE 22357
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3563
Mailing Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734
Business Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

IRS No.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-40388 | Film No.: 231314332
SIC: 2834 Pharmaceutical Preparations